Regulators, researchers, industry representatives and insurers from the Alzheimer’s community will join with experts from other therapeutic areas to:
Discuss lessons learned from other disease areas as well as from current Alzheimer’s prevention studies regarding biomarkers, clinical endpoints and tools that can inform regulatory science and payer assessments.
Identify the health outcomes, cost impacts and evidentiary requirements that will support access to future therapies and diagnostics.
Articulate strategies to advance awareness, diagnosis and post-diagnostic follow-up across our national health systems in order to prepare the market for treatments by 2025.
Dr. Rhoda Au will be presenting her research and thoughts regarding using research for one disease to advance research.